Published in Immunotherapy Weekly, September 10th, 2008
The immune system's tumor-fighting T cells work best when maximally activated. Scientists have achieved this by blocking molecules that dampen the cells' activation, or by removing a population of regulatory T cells that block the killing ability of tumor-specific T cells. But neither approach has worked well...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.